Adhera Therapeutics Inc. · OTC:ATRX
Adhera Therapeutics — Marina Biotech — Shareholder Meeting (October 2015)
16 slides from Adhera Therapeutics's shareholder meeting presentation, Oct 21, 2015
Slide 1: Nucleic Acid Therapeutics and Rare Diseases Annual Shareholder Meeting
Nucleic Acid Therapeutics and Rare Diseases Annual Shareholder Meeting San Diego, CA 16 October 2015
Slide 2: Forward Looking Statement
Forward Looking Statement This document contains forward - looking statements about Marina Biotech, Inc . (the “Company”) that are based on current management expectations . These statements reflect the Company’s current views with respect to uncertain future events and are based on imprecise estima
Slide 3: The Broadest Nucleic Acid Drug Discovery Capability in Sector
Marina has the capability to develop and deliver novel single - and double - stranded oligonucleotides . . . Marina Biotech – The Broadest Nucleic Acid Drug Discovery Capability in Sector 3 Marina Antisense siRNA microRNA mimics & antagomirs . . . w ith clinical demonstration in rare diseases and on
Slide 4: Our Assets and Strengths
» Proprietary chemistries for development of novel single - and double - stranded nucleic acid therapeutics » Multiple proprietary delivery systems with clinical demonstration of safety, activity and delivery outside the liver » Rare disease pipeline including a Phase 1 asset which has both FDA Orph
Slide 5: Chemistries for Single- and Double-Stranded Oligonucleotide Therapeutic Agents
Chemistries for Single - AND Double - Stranded Oligonucleotide Therapeutic Agents » Unlocked nucleobase monomers (UNM) – Allows development of double - stranded oligonucleotides that engage the RNAi pathway 5 » Conformationally restricted nucleotides (CRN) – Allows development of stable, high affini
Slide 6: Delivery Capability which is Unparalleled Within the Sector
Local Delivery DiLA2 Bladder Cancer Delivery Capability which is Unparalleled Within the Sector Systemic Delivery SMARTICLES 1 Relapsed/Refractory non - Hodgkin’s Lymphoma 2 Hepatocellular Carcinoma Oral Delivery tkRNAi 3 Familial Adenomatous Polyposis Targeted Delivery TrpCage - based Peptides Pros
Slide 7: Effective delivery of single-stranded and double-stranded nucleic acids
» Effective d elivery of single - stranded and double - stranded nucleic acids » ProNAi Therapeutics - PNT2258 (24mer single - stranded DNA decoy) » Mirna Therapeutics - MRX34 (19 - 21mer double - stranded microRNA mimic ) » Delivery to cell nucleus (PNT2258) and cell cytoplasm (MRX34) » Delivery ou
Slide 8: Only Orally Available RNAi Delivery Technology in Clinical Development - tkRNAi
Only Orally Available RNAi Delivery Technology in Clinical Development - tkRNAi ™ 8 » Non - pathogenic bacteria engineered to produce, deliver and release interfering RNA mediators (shRNA) to targeted tissue » Efficient delivery to the epithelium of the gastrointestinal tract via oral administration
Slide 9: Broad, Young and Issuing Intellectual Property Estate
Broad, Young and Issuing Intellectual Property Estate Technology US Issued or Allowed Foreign Issued or Allowed Worldwide Pending Biochemistry Unlocked Nucleobase Monomers (UNM) 2 6 25 Conformationally Restricted Nucleotides (CRN) 3 -- 12 Delivery Liposome Systems 14 82 44 Liposome Manufacturing Met
Slide 10: Rare Disease Drug Development
Rare Disease Drug Development 10
Slide 11: Clinical Program Pipeline
Clinical Program Pipeline Development Stage Program Myotonic Dystrophy Pre - IND Studies Phase I CEQ508 - FAP Duchenne Muscular Dystrophy IND 2017 2016 2017 2017 2018 2017 2017 2018 2019 Phase II Lead Selection CEQ508 has FDA Orphan Drug and Fast Track Designations 11 Clinical Program Pipeline Devel
Slide 12: Application of Drug Discovery Platform – Myotonic Dystrophy
Application of Drug Discovery Platform – Myotonic Dystrophy 12 Accumulation of altered DMPK mRNA in nucleus sequesters Muscleblind (MBNL1) protein resulting in loss - of - function 1. Steric Blocking » Displace/disrupt the MNBL - CUG n+x interaction 2. mRNA Translational Inhibition » RNAi or RNase H
Slide 13: Advantages of Marina's Approach
Advantages of Marina’s Approach » Broad nucleic acid drug discovery capability which is agnostic to mechanism of action » Versatile delivery platform with clinical demonstration of cell nucleus and cytoplasm delivery » Ability to take a multi - therapeutic approach to treating multiple biological sy
Slide 14: 2015 Accomplishments
2015 Accomplishments » Raised $ 1.5 MM through the issuance of convertible preferred stock and a prepaid milestone » Granted Food and Drug Administration Fast Track designation for CEQ508, an investigational RNAi therapeutic for the treatment of Familial Adenomatous Polyposis » Licensee Mirna Therap
Slide 15: Future Potential Partnering Opportunities
Future Potential Partnering Opportunities » Partner of Choice for Rare Diseases, i.e. Spinal Muscular Atrophy, Hemophilia, Friedrich’s Ataxia, Rare Oncology Indications » Biochemistries for single - and double - stranded constructs » Delivery technologies with unequaled clinical versatility » Abilit
Slide 16: Thank You
Thank You WOT